|Indications:||Diffuse Large B-Cell Lymphoma Follicular Lymphoma|
|Driver Mutations:||CREBBP, EP300
Mocetinostat is being evaluated in a Phase 2 study as a treatment for patients with relapsed and refractory Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) whose tumors carry genetic alterations of the CREBBP and EP300 genes. This study is being led by Dr. Anas Younes, Chief of Memorial Sloan Kettering's Lymphoma Service. The genetic sequence of the tumors of eligible patients will be analyzed to determine if those mutations are present before patients enroll in the clinical trial.